Prevalence of drug-resistant HIV-1 in rural areas of hubei province in the people's republic of China

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 1, 2009, Pages 1-8

  Luo, Minqi ^a   Liu, Huan ^a   Zhuang, Ke ^a   Liu, Li ^b   Su, Bo ^a   Yang, Rongrong ^a   Tien, Po ^a   Zhang, Linqi ^c   Gui, Xien ^a   Chen, Zhiwei ^b  

^a WUHAN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

China; Drug resistance; HAART; HIV 1; Subtype B'

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; POL PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; CHINA; CROSS-SECTIONAL STUDY; DEVELOPING COUNTRY; FEMALE; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; RURAL AREA; VIREMIA; VIRUS LOAD; VIRUS MUTATION; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MUTATION; PREVALENCE; RURAL POPULATION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHINA; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RURAL POPULATION; VIRAL LOAD;

EID: 64249169891     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31818ffcdc     Document Type: Article

References (37)

1. Zhang Y, Lu L, Ba L, et al. Dominance of HIV-1 subtype CRF01-AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med. 2006;3(11):e443.
2. Zhang L, Chen Z, Cao Y, et al. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in China. J Virol. 2004;78: 13591-13599.
3. Zhuang K, Gui X, Su B, et al. High prevalence of HIV infection among women and their children in Henan province, China. J Acquir Immune Defic Syndr. 2003;33:649-650.
4. Su B, Liu L, Wang F, et al. HIV-1 subtype B' dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China. AIDS. 2003;17:2515-2520.
5. Zhao R, Gao H, Shi X, et al. Sexually transmitted disease/HIV and heterosexual risk among miners in townships of Yunnan province, China. AIDS Patient Care STDS. 2005;19:848-852.
6. Cao YZ, Lu HZ. Care of HIV-infected patients in China. Cell Res. 2005; 15:883-890.
7. Zhang F, Au MC, Bouey PD, et al. The diagnosis and treatment of HIVinfected children in China: challenges and opportunities. J Acquir Immune Defic Syndr. 2007;44:429-434.
8. Lindstrom A, Ohlis A, Huigen M, et al. HIV-1 transmission cluster with M41L 'singleton' mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men. Antivir Ther. 2006;11: 1031-1039.
9. Zhang FJ, Maria A, Haberer J, et al. Overview of HIV drug resistance and its implications for China. Chin Med J (Engl). 2006; 119:1999-2004.
10. Zhang FJ, Pan J, Yu L, et al. Current progress of China's free ART program. Cell Res. 2005;15:877-882.
11. Kuiken C, Korber B, Shafer RW. HIV sequence databases. AIDS Rev. 2003;5:52-61.
12. Rhee SY, Gonzales MJ, Kantor R, et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31:298-303.
13. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15:119-125.
14. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med. 2006;14:125-130.
15. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194(Suppl 1):S51-S58.
16. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21: 215-223.
17. Walensky RP, Weinstein MC, Yazdanpanah Y, et al. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS. 2007;21:973-982.
18. Spacek LA, Shihab HM, Kamya MR, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis. 2006;42:252-259.
19. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41:1316-1323.
20. Li JY, Li HP, Li L, et al. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res. 2005;15:843-849.
21. Li J, Lu JF, Dong HH, et al. Phenotypic resistance of resistant strains of HIV type-1 subtype B in China. Chin Med J (Engl). 2006;119: 1972-1977.
22. Ma L, Sun J, Xing H, et al. Genotype and phenotype patterns of drugresistant HIV-1 subtype B' (Thai B) isolated from patients failing antiretroviral therapy in China. J Acquir Immune Defic Syndr. 2007;44:14-19.
23. Conway B, Wainberg MA, Hall D, et al. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS. 2001;15:1269-1274.
24. Clotet B. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. AIDS Rev. 2004;6:123-130.
25. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002; 16:369-379.
26. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:187-193.
27. Tam LW, Hogg RS, Yip B, et al. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naive individuals in a western setting. HIV Med. 2007;8: 267-270.
28. Zhou HY, Zheng YH, Zhang CY, et al. Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years. Viral Immunol. 2007;20:180-187.
29. Delaugerre C, Morand-Joubert L, Chaix ML, et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther. 2004;9:415-421.
30. Havlir D, Vella S, Hammer S. The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society. AIDS. 2002;16:7-9.
31. Shet A, Markowitz M. Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches. Curr Opin Investig Drugs. 2006;7: 709-720.
32. Simon V, Vanderhoeven J, Hurley A, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS. 2002;16:1511-1519.
33. Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet. 2005;365:1031-1038.
34. Antinori A, Trotta MP, Nasta P, et al. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients. Antivir Ther. 2006;11:233-243.
35. Dunn LA, Andrews KT, McCarthy JS, et al. The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis. Int J Antimicrob Agents. 2007;29:98-102.
36. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21:965-971.
37. Wanchu A, Kaur R, Bambery P, et al. Adherence to generic reverse transcriptase inhibitor-based antiretroviral medication at a tertiary center in north India. AIDS Behav. 2007;11:99-102.